{"id":48986,"date":"2025-11-25T19:55:29","date_gmt":"2025-11-25T11:55:29","guid":{"rendered":"https:\/\/flcube.com\/?p=48986"},"modified":"2025-11-25T19:55:30","modified_gmt":"2025-11-25T11:55:30","slug":"astrazenecas-durvalumab-wins-china-approval-for-stage-iii-nsclc-after-sequential-chemoradiotherapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48986","title":{"rendered":"AstraZeneca&#8217;s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy"},"content":{"rendered":"\n<p><strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ: AZN<\/a>) announced that <strong>Imfinzi (durvalumab)<\/strong> received <strong>National Medical Products Administration (NMPA) approval<\/strong> for patients with <strong>unresectable Stage III NSCLC<\/strong> who have no disease progression after <strong>platinum-based concurrent or sequential chemoradiotherapy<\/strong> and lack EGFR\/ALK alterations, based on the <strong>PACIFIC-5 Phase\u202f3 trial<\/strong> demonstrating a <strong>25% reduction in disease progression or death risk<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Imfinzi (durvalumab)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>AstraZeneca (NASDAQ: AZN)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Expanded indication<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Unresectable Stage III NSCLC post cCRT or sCRT (no EGFR\/ALK alterations)<\/td><\/tr><tr><td><strong>Study Basis<\/strong><\/td><td>PACIFIC-5 Phase\u202f3 trial<\/td><\/tr><tr><td><strong>Primary Result<\/strong><\/td><td>25% reduction in disease progression\/death risk vs. placebo<\/td><\/tr><tr><td><strong>Historical Context<\/strong><\/td><td>First approved in China in 2019 for cCRT consolidation; now expands to sCRT patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Humanized <strong>PD-L1 monoclonal antibody<\/strong> that restores anti-tumor T\u2011cell activity<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>First immunotherapy<\/strong> approved for Stage III NSCLC consolidation; now the <strong>first to cover both cCRT and sCRT<\/strong> patient populations<\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> PACIFIC-5 subgroup analysis confirmed benefit regardless of chemoradiotherapy sequencing, addressing a <strong>previously underserved sCRT patient group<\/strong> (~30% of Stage III NSCLC patients)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-pacific-5-trial\">Clinical Evidence \u2013 PACIFIC-5 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Durvalumab vs. Placebo<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease Progression\/Death Risk Reduction<\/strong><\/td><td>25% (HR\u202f=\u202f0.75; p\u202f&lt;\u202f0.01)<\/td><\/tr><tr><td><strong>Overall Survival Trend<\/strong><\/td><td>Favorable (interim analysis)<\/td><\/tr><tr><td><strong>cCRT Subgroup<\/strong><\/td><td>Consistent benefit<\/td><\/tr><tr><td><strong>sCRT Subgroup<\/strong><\/td><td>Consistent benefit (key expansion)<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Manageable; consistent with prior PACIFIC data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Stage III NSCLC Incidence<\/strong><\/td><td>~85,000 new cases annually<\/td><\/tr><tr><td><strong>Eligible for Consolidation<\/strong><\/td><td>~60% (51,000 patients)<\/td><\/tr><tr><td><strong>sCRT Patient Share<\/strong><\/td><td>~30% (15,300 patients)<\/td><\/tr><tr><td><strong>Current Durvalumab Sales (China)<\/strong><\/td><td>\u00a52.1\u202fbillion (~$290\u202fmillion)<\/td><\/tr><tr><td><strong>Peak Sales Forecast (Expanded Indication)<\/strong><\/td><td><strong>\u00a53.5\u20114.2\u202fbillion<\/strong> (~$480\u2011580\u202fmillion) by 2028<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>45\u201150% of eligible Stage III NSCLC patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reimbursement Path:<\/strong> NRDL listing secured for cCRT indication; expansion for sCRT likely <strong>automatic<\/strong> under existing agreement<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> <strong>No direct competitors<\/strong> in sCRT consolidation; reinforces durvalumab&#8217;s leadership in Stage III NSCLC<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens AstraZeneca&#8217;s <strong>IO franchise<\/strong> in China, complementing Imfinzi&#8217;s approvals in extensive-stage SCLC and biliary tract cancer<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding durvalumab&#8217;s commercial performance, market penetration, and regulatory exclusivity. Actual results may differ materially due to risks including competitive responses, reimbursement negotiations, and real\u2011world clinical adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48987,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,770,871,18,15],"class_list":["post-48986","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-az","tag-nasdaq-azn","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca&#039;s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval for patients with unresectable Stage III NSCLC who have no disease progression after platinum-based concurrent or sequential chemoradiotherapy and lack EGFR\/ALK alterations, based on the PACIFIC-5 Phase\u202f3 trial demonstrating a 25% reduction in disease progression or death risk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48986\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca&#039;s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval for patients with unresectable Stage III NSCLC who have no disease progression after platinum-based concurrent or sequential chemoradiotherapy and lack EGFR\/ALK alterations, based on the PACIFIC-5 Phase\u202f3 trial demonstrating a 25% reduction in disease progression or death risk.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48986\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T11:55:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T11:55:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca&#8217;s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy\",\"datePublished\":\"2025-11-25T11:55:29+00:00\",\"dateModified\":\"2025-11-25T11:55:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986\"},\"wordCount\":361,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2502-1.webp\",\"keywords\":[\"AstraZeneca\",\"AZ\",\"NASDAQ: AZN\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48986#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48986\",\"name\":\"AstraZeneca's Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2502-1.webp\",\"datePublished\":\"2025-11-25T11:55:29+00:00\",\"dateModified\":\"2025-11-25T11:55:30+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval for patients with unresectable Stage III NSCLC who have no disease progression after platinum-based concurrent or sequential chemoradiotherapy and lack EGFR\\\/ALK alterations, based on the PACIFIC-5 Phase\u202f3 trial demonstrating a 25% reduction in disease progression or death risk.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48986\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2502-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2502-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca's Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48986#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca&#8217;s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval for patients with unresectable Stage III NSCLC who have no disease progression after platinum-based concurrent or sequential chemoradiotherapy and lack EGFR\/ALK alterations, based on the PACIFIC-5 Phase\u202f3 trial demonstrating a 25% reduction in disease progression or death risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48986","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy","og_description":"AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval for patients with unresectable Stage III NSCLC who have no disease progression after platinum-based concurrent or sequential chemoradiotherapy and lack EGFR\/ALK alterations, based on the PACIFIC-5 Phase\u202f3 trial demonstrating a 25% reduction in disease progression or death risk.","og_url":"https:\/\/flcube.com\/?p=48986","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-25T11:55:29+00:00","article_modified_time":"2025-11-25T11:55:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48986#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48986"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca&#8217;s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy","datePublished":"2025-11-25T11:55:29+00:00","dateModified":"2025-11-25T11:55:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48986"},"wordCount":361,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48986#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502-1.webp","keywords":["AstraZeneca","AZ","NASDAQ: AZN","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48986#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48986","url":"https:\/\/flcube.com\/?p=48986","name":"AstraZeneca's Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48986#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48986#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502-1.webp","datePublished":"2025-11-25T11:55:29+00:00","dateModified":"2025-11-25T11:55:30+00:00","description":"AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval for patients with unresectable Stage III NSCLC who have no disease progression after platinum-based concurrent or sequential chemoradiotherapy and lack EGFR\/ALK alterations, based on the PACIFIC-5 Phase\u202f3 trial demonstrating a 25% reduction in disease progression or death risk.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48986#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48986"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48986#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502-1.webp","width":1080,"height":608,"caption":"AstraZeneca's Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48986#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca&#8217;s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48986"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48986\/revisions"}],"predecessor-version":[{"id":48988,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48986\/revisions\/48988"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48987"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}